Company Overview
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -53.54% |
| 6 Months: | -28.28% |
| 3 Months: | -18.88% |
| 1 Month: | -1.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TLSA Tiziana Life Sciences Ltd PHARMA | 0.99 | -6.19 | $125.99M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | - | - | - | - |
| Gross Profit | 0 | - | - | - | - |
| Operating Expenses | - | 14.59M | 17.98M | 15.79M | 21.13M |
| Operating Income | - | -14.59M | -17.98M | -15.79M | -21.13M |
| EBITDA | - | -15.31M | -17.14M | -16.62M | -18.18M |
| Interest Expense | - | 38.00K | 10.00K | 6.00K | 18.00K |
| Pretax Income | - | -15.40M | -17.24M | -16.75M | -18.43M |
| Tax Provision | - | 0 | 449.00K | -4.88M | 0 |
| Net Income | - | -15.40M | -17.69M | -11.86M | -18.43M |
| Diluted EPS | - | -0.15 | -0.17 | -0.11 | -0.16 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 26.48M | 12.18M | 11.28M | 11.49M |
| Current Assets | - | 24.28M | 7.34M | 7.51M | 8.55M |
| Cash & Equivalents | - | 18.12M | 1.18M | 3.72M | 4.01M |
| Inventory | - | - | - | - | - |
| Receivables | - | 5.99M | 6.05M | 3.69M | 4.26M |
| Total Liabilities | - | 6.91M | 6.65M | 7.35M | 11.44M |
| Current Liabilities | - | 6.66M | 6.54M | 7.35M | 11.21M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 365.00K | 247.00K | 106.00K | 456.00K |
| Total Equity | - | 19.57M | 5.54M | 3.94M | 52.00K |
| Shares Outstanding | - | 102.27M | 103.09M | 111.46M | 120.51M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -19.61M | -15.70M | -1.53M | -12.85M |
| Investing Cash Flow | - | -4.00M | -1.25M | -71.00K | 3.04M |
| Financing Cash Flow | - | -55.00K | 40.00K | 4.50M | 10.01M |
| Capital Expenditure | -22.00K | - | - | -19.00K | -21.00K |
| Free Cash Flow | - | -19.61M | -15.70M | -1.54M | -12.87M |
| Net Change in Cash | - | -23.67M | -16.91M | 2.91M | 202.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -78.7% | -319.6% | -301.4% | -35,444.2% |
| ROCE % | - | -73.6% | -318.6% | -401.3% | -7,388.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dauntless Investment Group, LLC | 0.96% | 1.16M | $1.05M |
| 2 | Mid-american Wealth Advisory Group, Inc. | 0.27% | 323.24K | $292.73K |
| 3 | Zhang Financial LLC | 0.10% | 125.95K | $114.06K |
| 4 | Goldman Sachs Group Inc | 0.10% | 119.24K | $107.98K |
| 5 | Focus Partners Wealth | 0.07% | 79.36K | $71.87K |
| 6 | Citadel Advisors Llc | 0.07% | 80.22K | $72.65K |
| 7 | Geode Capital Management, LLC | 0.06% | 78.20K | $70.82K |
| 8 | UBS Group AG | 0.06% | 72.88K | $66.00K |
| 9 | HSBC Holdings PLC | 0.05% | 62.44K | $56.54K |
| 10 | Morgan Stanley | 0.04% | 53.66K | $48.59K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLSA
$TLSA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQUFgtZ2pBVXZteUQzbk1PSnZPQmZuOG94Q1ZFeDZIenVRczBfRHpGOHA0U3ctR2s1NmtId19mVTFxSnhxRGpTYXRhaElTUmUwb2RDb242TllxTHl6OXpVdHNoM09xNy1pX05KSzlhLVlhX1ZqUUstWjRyR04yWmw3MHBhU2lhcU91bjJwaW…
Why Is TLSA Stock Rising Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTlp2WDBGeHlTTVhDaVlRTzBUZzk4ZTVrMFU1cDVLX25SRTdDVnRZbERseDJJbXV1VTVtVHJlNXM4VE1VNDVYS00wMzRTR04tWnRlMllUX3dMcFRoekNXdzBxSENmZHRRMFBmS0hwSmtMeV9LUm01d3hZREp6TjItQTVnTlpKTFhlY2hrRV…
TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNZmlEZUlaeFRHRnhUQTRVb2Rlb1JPZ0JTQUxEZzI2TUk0SHlfRTItbnlMalhtdVdlUGRVYlYtbGJuOUIweVFGLUNBSFVFeEs0MklOSERIaWkxTHlOME4yWExlNjJNbks5ZGUwYWFnMGl4a19jU0c2UEQ5WHNXdDZHWTdVdVBwdlRGUGFnNm…
TLSA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5JekpIaS05MXdsUTl0aDQycXFLR2tzOElCWnozZWpWdGhlM3JkTTNmSldRWEkxQWpQbXBiMTNiSjF0SzJUcmluaVJjQjBwTDhidTJzYnlVMjhsZktDdVVXb1RpeS1lQ2NPcHRKdGlnRzVmSkRRd2RDQkxB?oc=5" target="_blank">TLS…
More Analysts Say Hold Than Buy on Tesla. The Price Target Went Up Anyway. - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQVU9kX1JjR2ZMVXJETU5jR05CYXpxVDM3MXVHcFlnVEFZbjhCRHBIOXNHMzc1X3pWNGNGSVJWQTBEWnQwd0t3QTdPaC14d01mUTlUVU5MMFRzN2hkV1hBRE9ncUtJbGphRUp5WUFYbDVLUHd1UjJMMWloSHlzaGd2eFJjTUJBVVN2bG5QdG…
Tesla Stock Tumbles After Big Earnings Miss - Investopedia
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNRHJGVmh5QUNOcjlYN0xCQWpObVRhdXJ6a1FaOGRlWkVUd1hOcGMxNTA5ajFPYWdHQkVzaVM0R01BOHkxelQ3WmtjbTdvTFJLeXBVSURUeU41LTR5Yjdocl85bmxFU0MtM241LUFvWmhxNkItWkJLWkZPd2p1YkQ4ckloUXR3cVFNT2tTST…
TLSA — Frequently Asked Questions
What is the current share price of Tiziana Life Sciences Ltd (TLSA)?
As of 2026-09-19 21:16 PDT, Tiziana Life Sciences Ltd (TLSA) trades at $0.99 on NasdaqCM. Its 52-week range is $0.89 to $2.29.
What is the market capitalisation of TLSA?
Tiziana Life Sciences Ltd (TLSA) has a market capitalisation of $125.99M on NasdaqCM.
What is the P/E ratio of TLSA?
TLSA trades at a trailing price-to-earnings (P/E) ratio of -6.19. The industry average P/E is 24.83.
Is TLSA a good stock to buy?
This page provides a data-driven analysis of Tiziana Life Sciences Ltd (TLSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.